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Problems with ethical approval and how to fix them:
lessons from three trials in rheumatoid arthritis
Jonathan Mendel and colleagues call for greater transparency on ethics committee decisions to
improve trial design
Jonathan Mendel lecturer in human geography 1, Ben Goldacre senior clinical research fellow 2,
Edzard Ernst emeritus professor 3, Samuel Whittle consultant rheumatologist 4
1Geography, School of Social Sciences, University of Dundee, Dundee, DD1 4HN, UK; 2Centre for Evidence-Based Medicine, University of Oxford,
Oxford, UK; 3Peninsula Medical School, University of Exeter, Exeter, UK; 4Discipline of Medicine, University of Adelaide, Australia
Clinical trials are subject to costly and onerous regulation that
aims to ensure they are well designed, with risks to participants
minimised wherever possible, and any serious outstanding risks
communicated clearly to participants. We set out to assess how
well current regulatory frameworks meet these aims, and the
extent to which the relevant regulatory documentation can be
accessed for independent scrutiny, using three recent trials of
interventions for rheumatoid arthritis.
A recent study reported that over 10 000 people with rheumatoid
arthritis have been randomised to control groups receiving
ineffective treatment in trials of biological disease modifying
antirheumatic drugs, risking “irreversible deterioration in
condition.”1 We investigated the process of ethical approval,
and the information given to patients, for two trials of
ocrelizumab included in this study (STAGE2 and FEATURE3).
We also reviewed documents for a homeopathy trial in
rheumatoid arthritis because problems with ethical approval
and informed consent in complementary and alternative
medicine have been reported.4Rheumatoid arthritis is a common
disease for which many new therapies have been developed
over the past two decades; it is therefore ideal for exploring
these issues, which are relevant to clinical trials in all areas of
medicine.
Barriers to accessing ethics documents
We experienced extensive delays and challenges obtaining
documents and information for all the trials. Genentech/Roche
sponsors both the STAGE and FEATURE trials. JM approached
the company by email and phone to ask about the justification
for using a placebo control group, request copies of documents
and correspondence with the ethics committee on this issue,
and request copies of documents given to participants (a
template consent form and patient information sheet). Roche
initially refused, stating that the Association of the British
Pharmaceutical Industry code of conduct prohibits commercial
promotion of drugs directly to patients. Although JM is not a
healthcare professional, the request gave his academic email
address and explained the purpose of our study. We were
therefore surprised to see this regulation being cited as a reason
not to share information. BG (one of three medical doctors on
the project) then contacted Roche. However, while Roche did
send us parts of the documentation from the ethical approval
process, it they declined a request for copies of all
correspondence with this ethics committee, explaining
“ocrelizumab is undergoing regulatory assessment and this
information forms part of the confidential filing dossier.” We
then requested these documents from the Health Research
Authority, under the UK’s Freedom of Information Act.
We chose the homeopathy trial at Wrightington, Wigan, and
Leigh NHS Foundation Trust because it was highlighted on
social media5 as an example of ethical problems in
complementary and alternative medicine research. We made a
freedom of information request to the trust for a copy of all
documents submitted to the ethics committee in relation to this
trial, and all related correspondence to and from this committee.
The trust replied promptly, but many relevant documents were
missing. It was only after extensive correspondence that we
eventually received all the requested information.
We reviewed the trial documentation to assess (where relevant)
how the use of a placebo comparator was justified; how well
the trial processes met ethical expectations for research on
human participants; and whether adequate information on
shortcomings or risks with the comparator was given to patients.
Problems with risk mitigation
Ocrelizumab trials
FEATURE and STAGE randomised patients with active
rheumatoid arthritis and inadequate responses to methotrexate
to treatment with either ocrelizumab or placebo plus
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methotrexate for a prolonged period (up to 48 weeks in STAGE)
before reallocation to active therapy or open label treatment
with ocrelizumab. As rituximab (which has the same molecular
target as ocrelizumab) was an established treatment for active
rheumatoid arthritis, this potentially deprived participants of
effective treatment for as much as a year. Inadequate treatment
can lead to irreversible structural damage, additional pain, and
functional impairment.
FEATURE’s ethics application acknowledges that “the main
ethical concern with this study is the need for the control arm
to receive placebo ocrelizumab infusions. However, this group
will receive methotrexate throughout the trial, which is
considered standard first-line therapy in many institutions and
the participants can continue with analgesics, non-steroidal
anti-inflammatory drugs (NSAIDs) and steroids if receiving
these medications at a stable dose prior to the trial.”
Methotrexate is used as first line treatment, but trial participants
had already had unsuccessful treatment with methotrexate and
so were no longer at the first line stage. The applicants quote a
single cohort study by Kapral and colleagues6 as evidence that
methotrexate is effective, even in those for whom it has
previously been ineffective. However, the findings of this study
cannot be readily generalised, and the initial dose of
methotrexate (median 10 mg) was much lower than in
FEATURE (16.3 mg at baseline). Most patients in Kapral’s
cohort whose initial dose of methotrexate was similar to that in
FEATURE did not respond to “re-employment.” Instead of
relying on this study, discussion of risk mitigation could have
been grounded in a review of the available evidence.
Another ethical problem with the trials’ design is that rescue
therapy was permitted but not mandated. The presence of real
or perceived barriers to escalating treatment through rescue
therapy is supported by the fact that only 26% of placebo treated
participants in STAGE received rescue drugs, despite active
disease at baseline and previous lack of response to
methotrexate. Furthermore, only 27.6% of the placebo group
achieved a 20% improvement in a composite measure of disease
activity (ACR20), equivalent to a minor clinical response, at
week 48.
Participants in STAGE who received the active drug had a
significant structural benefit compared with controls, confirming
that patients taking placebo were disadvantaged despite the
availability of rescue therapy. This risk could have been
mitigated if other biological drugs with evidence of effectiveness
had been used as comparator.
A research ethics committee looking at FEATURE asked for
“clarification regarding whether the patients in the placebo arm
would be deprived of other treatment options.” However, it
seems to have accepted reassurance that “patients would be able
to take additional medications (NSAIDS and steroids) as needed,
and that there were many options for escape therapy.”We found
no evidence that the committee further discussed this key issue
or using another biological drug as an active comparator (despite
their widespread use at this stage of disease).
Homeopathy
The exclusions listed on the ethics committee form for the
homeopathy trial differ from those in the research protocol
(box), but there is no evidence that the committee raised this.
Moreover, some of the trial’s exclusion criteria seem unjustified
since homeopathic remedies beyond the C12 potency (that is,
diluted 12 times at a ratio 1:100 resulting in a final dilution of
1:1024) contain no active molecules to, for example, interact
with biological drugs.
Failure to communicate risks of placebo
during informed consent
Roche supplied only an excerpt from an application to a UK
ethics committee for the FEATURE study. This recognised that
“the main ethical concern with this study is the need for the
control arm to receive placebo ocrelizumab infusions.” However,
the committee did not ensure that participants were told this.
There is room for professional debate on the extent of specific
risks, and it is not necessary to share all information seen by
the committee with participants. However, it is important that
participants are aware of major concerns with the research so
that they can make an informed choice; the fact that the control
group’s treatment was seen as the main ethical concern suggests
that it should have been shared with participants. At the least
the committee might be expected to discuss whether this
information should be shared.
The consent forms for the two drug trials did not explicitly state
the additional risks to members of the placebo control group
such as increased pain, impairment, and permanent structural
damage. Also, while the risks of corticosteroids are explained,
the consent forms do not make explicit the risks of increased
doses as rescue therapy.
Failure to communicate methodological
shortcomings and results of previous
research
The ethics committee approved the homeopathy trialists’
outlined procedure for soliciting informed consent. However,
the information provided was problematic. The patient
information (as revised after ethics review) stated that
homeopathic remedies are “usually based onminerals or herbs.”
This implies that they contain active ingredients, but remedies
beyond the C12 potency contain no activemolecules. The patient
information stated that “there is currently little clinical evidence
about the efficacy of homeopathic remedies” but did not state
that the totality of the available evidence fails to show that
highly dilute homeopathic remedies are effective beyond
placebo.7
The patient information states that the “research may benefit
you or future patients because the findings will inform
treatment.” The sponsoring NHS trust declared that “an
appropriate process of scientific critique has demonstrated that
this research proposal is worthwhile and of high scientific
quality.” However, it is hard to see how a small non-randomised
trial of homeopathy—which, the ethics committee noted, covers
similar ground to previous higher quality trials—will alter
current best evidence. While some or all patients may still have
made an informed choice to participate, knowing the
shortcomings, the ethics committee form does not discuss
whether the study is a good use of patients’ time or NHS
resources.
Towards greater transparency
Our analysis suggests it is naive to accept ethics committee
approval alone as evidence that ethical concerns have been
appropriately reviewed, with the trial appropriately designed,
best evidence considered, and harms minimised. Similarly,
statements that informed consent was obtained do not guarantee
that participants were given the information that a broader range
of clinicians, researchers, and patients would regard as
appropriate for informed consent. We recognise that there is
room for disagreement on the concerns raised by any individual
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Inconsistencies in homeopathy ethics documentation
The homeopathy trial ethics committee form states that patients taking biologically active drugs or who have used homeopathy in the past
six months are excluded; however, the only exclusions mentioned on the research protocol are people who are “under 18, have previous
experience of homeopathic treatment, are pregnant or breast feeding or have severe co-morbidities that might affect RA treatment.” The
ethics form does not mention exclusion of people who are breast feeding or under 18.
trial or document, but a better route is transparency: it should
be straightforward for anyone to access the details of the ethical
review and the actual information given to patients in order to
critically appraise them. At present, there are substantial barriers
to accessing the relevant documents.
These issues are important throughout medicine. In our
experience, similar methodological shortcomings are
characteristic of many studies of biological drugs for rheumatoid
arthritis,1 of complementary and alternative medicines,4 and of
other areas of medical research. While a systematic review of
a larger sample of trials would be desirable, the difficulties in
accessing basic ethics documents means that such scrutiny is
unlikely to be feasible.
Poor regulation of research can cause direct harm to patients
and undermine its credibility. However, the failings identified
could be improved. We suggest the following, which reflect
established recommendations for medical research:
Systematically review evidence relating to current and
proposed treatments—A robust understanding of the possible
utility, risks, and benefits of a proposed trial requires
examination of what is already known about the topic. In
the examples above, a systematic review could have ensured
that a much clearer picture of the evidence was available to
the ethics committee and participants. Although a systematic
review is not sufficient (for example, investigators might
produce a highly biased review), having such a review
available for critical scrutiny will be an improvement.
Assess the quality of the proposed research, and tell patients
about this—Ideally, ethics committees or other appropriate
bodies should critically evaluate the quality of the evidence
submitted by investigators and the research proposal. While
there will be a large grey area, some trials are sufficiently
unlikely to prove informative that committees should be able
to reject them. If the ethics process permits poor quality
research, the limitations of the research should be made
explicit to patients so they can make an informed choice
about participation. This might become part of what Iain
Chalmers describes as a “patient-led good controlled trials
guide.”8
Ensure that risks are appropriately mitigated—Including
risks associated with placebo.
Give patients a summary of existing evidence and of any
risks of participation—When patients face risks from
participation in a trial, or where previous research casts doubt
on a therapy’s plausibility, this should be clearly and
explicitly explained.
Make all documentation around ethical approval and consent
freely available—Blank consent forms should be made
publicly available alongside trial registration, accompanied
by the participant information sheet. Similarly,
correspondence with ethics committees and other bodies
with a similar role should routinely be made publicly
available. This will allow ethics processes to be
independently reviewed, publically discussed, and learnt
from.
Larger scale research is needed to investigate the prevalence of
the problems we have identified with ethical approval and
informed consent. Such studies would allow assessment of
differences between committees and facilitate accountability.
At minimum, a review of transparency policies for institutional
and national ethics review bodies is needed. Ethics processes
are important to society, and should be open to public scrutiny.
Openness is vital, both to minimise avoidable participant harms
and to maintain public trust.
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